BSE Live
Nov 14, 12:00Prev. Close
1208.85
Open Price
1210.05
Bid Price (Qty.)
1213.20 (13)
Offer Price (Qty.)
1214.75 (32)
NSE Live
Nov 14, 12:00Prev. Close
1210.20
Open Price
1210.20
Bid Price (Qty.)
1213.70 (41)
Offer Price (Qty.)
1213.90 (11)
| Profit & Loss account of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 22,737.96 | 19,225.93 | 16,232.87 | 14,844.79 | 13,709.74 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 36.80 | 180.32 | 160.57 | |
| Revenue From Operations [Net] | 22,737.96 | 19,225.93 | 16,196.07 | 14,664.47 | 13,549.17 | |
| Total Operating Revenues | 23,098.51 | 19,563.55 | 16,463.03 | 14,909.54 | 13,794.65 | |
| Other Income | 191.87 | 155.32 | 101.98 | 115.89 | 203.80 | |
| Total Revenue | 23,290.38 | 19,718.87 | 16,565.01 | 15,025.43 | 13,998.45 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 7,724.98 | 7,444.99 | 5,629.38 | 5,184.92 | 4,825.56 | |
| Purchase Of Stock-In Trade | 2,112.11 | 1,943.20 | 1,605.88 | 1,558.54 | 1,429.42 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -101.86 | -675.55 | -485.66 | -309.20 | -92.88 | |
| Employee Benefit Expenses | 3,219.18 | 2,584.87 | 2,130.84 | 1,767.76 | 1,542.62 | |
| Finance Costs | 305.13 | 262.60 | 77.72 | 66.72 | 256.70 | |
| Depreciation And Amortisation Expenses | 966.71 | 667.95 | 557.97 | 427.63 | 392.37 | |
| Other Expenses | 5,279.79 | 4,314.10 | 3,810.84 | 3,273.24 | 2,901.81 | |
| Total Expenses | 19,506.04 | 16,542.16 | 13,326.97 | 11,969.61 | 11,255.60 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 3,784.34 | 3,176.71 | 3,238.04 | 3,055.82 | 2,742.85 | |
| Exceptional Items | -26.13 | -88.06 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 3,758.21 | 3,088.65 | 3,238.04 | 3,055.82 | 2,742.85 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 956.96 | 712.07 | 712.30 | 691.70 | 710.65 | |
| Less: MAT Credit Entitlement | 0.00 | 51.00 | 43.32 | 64.28 | 0.00 | |
| Deferred Tax | -43.44 | 65.78 | 149.29 | 132.23 | 10.06 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 913.52 | 726.85 | 818.27 | 759.65 | 720.71 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 2,844.69 | 2,361.80 | 2,419.77 | 2,296.17 | 2,022.14 | |
| Profit/Loss From Continuing Operations | 2,844.69 | 2,361.80 | 2,419.77 | 2,296.17 | 2,022.14 | |
| Profit/Loss For The Period | 2,844.69 | 2,361.80 | 2,419.77 | 2,296.17 | 2,022.14 | |
| Minority Interest | 1.45 | 0.23 | 0.26 | 0.47 | 1.50 | |
| Consolidated Profit/Loss After MI And Associates | 2,830.97 | 2,364.73 | 2,423.17 | 2,301.66 | 2,025.09 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 48.00 | 40.00 | 41.00 | 39.00 | 35.00 | |
| Diluted EPS (Rs.) | 48.00 | 40.00 | 41.00 | 39.00 | 35.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 175.78 | 146.48 | 219.71 | 114.11 | 134.37 | |
| Tax On Dividend | 12.79 | 13.86 | 44.73 | 23.23 | 27.36 |
14.11.2025
12.11.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
12.11.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL